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in pre-pubertal children with idiopathic GH Deficiency (GHD) and Turner Syn-
drome (TS). The long-term prediction of height was validated in new cohorts of
pre-pubertal children with GHD (n 664) or TS (n607) from KIGS. RESULTS:When
height was simulated from GH start in GHD, the predicted mean (SD) gain after 4
years was 30.4 (3.4) cm; the observed height gain was 30.0 (5.0) cm. In TS the
corresponding predicted and observed mean gains were 27.2 (2.2) and 26.5 (3.8) cm.
CONCLUSIONS: Sequential application of annual KIGS growth prediction models
permits accurate simulation of height development during the first four years of
GH treatment in GHD and TS and is applicable for patient groups from GH start.
Long-term growth simulation helps managing patient’s expectations and facili-
tates an individualised, cost effective growth hormone (GH) therapy in children.
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OBJECTIVES: To establish whether there are subsets of women with idiopathic
menorrhagia who experience differential health-related quality of life (HRQL) ben-
efits with LNG-IUS treatment, and which factors could be attributed to those
differences. METHODS: Data for women with idiopathic menorrhagia residing in
India, Russia and Turkey were derived from a prospective, 12-month observational
study. Latent profile analysis (LPA) was used to identify unknown subgroups of
differential responders on the Mental Component Summary (MCS) of the SF-36v2.
Post hoc analyses were performed to characterize identified subgroups using base-
line and 12 month data. RESULTS: Overall improvement in MCS scores from base-
line to 12 months was 8.4 points. LPA analyses revealed two distinct subsets of
patients: one smaller subset (30% of the sample) showed a smaller improvement
(2.3 points) than the improvement overall and are thus referred to as ‘partial-
responders.’ A larger subgroup (70% of the sample) was identified with a much
greater improvement (11.3 points) than that overall, thus referred to as ‘respond-
ers’. Post hoc analyses revealed statistically significant differences between MCS
responders and partial-responders: significantly greater proportion of MCS re-
sponders had university-level education, were more likely to reside in India or
Russia and be employed, reported‘none’ or ‘light’ bleeding intensity while on treat-
ment, reported greater patient and physician satisfaction with treatment, and had
higher 12-month haemoglobin levels. CONCLUSIONS: Understanding of heteroge-
neity of treatment response is critical for routine clinical practice. Application of
LPA identified two distinct subgroups of women showing differential response to
HRQL from LNG-IUS treatment. All women showed a statistically significant im-
provement in HRQL as measured by the MCS, although this improvement was
greater for a large subset of women in the sample. Country-level differences in
treatment effect on mental HRQL may be subject to cultural or health care practice
differences.
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OBJECTIVES: To evaluate the tolerability of oral long-acting opioids (LAOs) in pa-
tients treated for chronic pain. Opioid analgesia is the mainstay of treatment for
moderate to severe chronic pain. While highly effective in relieving pain, it is
limited by adverse events (AEs), especially gastrointestinal and central nervous
system events. AEs may result in additional treatment costs and discontinuation of
therapy, compromising pain management.METHODS:A systematic review of Eng-
lish-language literature published through February 2009 was performed. Random-
ized controlled trials comparing commonly used oral schedule II LAOs with placebo
or another opioid were included. Data on pain measures and pre-specified AEs
(nausea, vomiting, somnolence, constipation, headache, pruritus, and dry mouth)
were collected from each study. For descriptive statistics, treatment-arm data on
tapentadol, oxycodone, oxymorphone, morphine, hydromorphone, and placebo
were pooled across trials. Direct and indirect meta-analyses were performed to
compare AE rates of individual LAOs with placebo and with tapentadol. RESULTS:
Seventy-one published studies met the inclusion criteria. Tapentadol was associ-
ated with the lowest incidence of AEs across the 5 LAOs, with the exception of
headache and dry mouth. The AE incidences for tapentadol, oxycodone, oxymor-
phone, morphine, hydromorphone, and placebo were: nausea: 19.5%, 32.5%, 38.8%,
29.7%, 33.5%, and 8.4%, respectively; vomiting: 7.9%, 16.1%, 19.9%, 15.5%, 15.1%, and
2.4%; somnolence: 10.2%, 24.8%, 18.3%, 33.6%, 50.4%, and 3.7%; constipation: 14.1%,
34.7%, 26.9%, 43.2%, 27.6%, and 6.1%; headache: 13.3%, 11.3%, 9.7%, 3.8%, 5.7%, and
10.4%; pruritus: 5.2%, 16.6%, 15.7%, 20.1%, 20.8%, and 1.5%; and dry mouth: 6.8%,
11.8%, 10.0%, 31.4%, and 2.6% (placebo), with no data for hydromorphone. Indirect
meta-analyses further revealed a significantly favorable tolerability profile of tap-
entadol when compared to oxycodone, oxymorphone, and morphine.
CONCLUSIONS: Opioid-associated AEs are common, but the incidence varied
across the LAOs reviewed. Indirect meta-analyses suggest that tapentadol has a
better tolerability profile than other LAOs.
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OBJECTIVES: Immuno-mediated inflammatory diseases (IMIDs) may coexist
within the same patient. Anti-TNFs have been shown to be effective at treating
IMIDs. The present study aimed at evaluating the prevalence of the coexistence of
selected IMIDs and other comorbidities, characterizing the patient population and
assessing the use of anti-TNFs from a populational standpoint. METHODS: A co-
hort of patients who had received at least one diagnosis of rheumatoid arthritis
(RA), ankylosing spondylitis, psoriatic arthritis, psoriasis (Ps), Crohn’s disease (CD),
ulcerative colitis, or uveitis, between January 2005 and December 2009, was ran-
domly selected from the Régie de l’assurance-maladie du Québec (RAMQ) data-
bases. The coexistence and temporality of the above diagnoses as well as other
predefined chronic conditions were assessed. Characterization and stratification
according to demographics and anti-TNF use (use or no-use) were also performed.
RESULTS: A total of 80,566 patients who had at least one diagnosis of an IMID were
included in this cohort. The study population was on average 53.6 years old (SD:
21.3 years) and was in majority female (60,1%). Most common primary diagnoses
were RA (33.4%), Ps (33.8%) and CD (22.8%) while 3.9% of patients had received at
least one prescription of an anti-TNF medication. In this population, 9.1% of pa-
tients presented with one coexisting IMID diagnosis and 1.4% with 2 or more coex-
isting diagnoses. Among patients who had used an anti-TNF, 27.9% had one coex-
isting IMID diagnosis and 9.1% had 2 or more coexisting diagnoses. Other chronic
comorbidities were found in 82.8% of patients. The most frequent comorbidities
were hypertension (37.2%), cardiovascular diseases (22.4%), diabetes (16.7%) and
osteoporosis (15.7%).CONCLUSIONS:Coexisting IMID diagnoses and comorbidities
are often present in patients with IMID and greatly contribute to the burden of
disease.
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OBJECTIVES: Obesity is considered a major Public Health issue in most developed
countries nowadays for its wide spread across population groups, as well as its
contribution to the development of chronic diseases. Our objective was to estimate
and better understand the impact of progressively increasing Body Mass Index
(BMI) on diagnosed Diabetes, Heart Attack (HA), Hypertension, Chronic Anxiety
(CA) and Chronic Depression (CD) in adult population. METHODS: Retrospective
analysis of the Spanish 2009 European Health Survey System data base was con-
ducted. Data from population under 18 years old or with BMI under 18.5 or with not
reported BMI were excluded. Sample size of 19,880 adults (89.6% of the initial sam-
ple) was available for analysis. A logistic regression model was constructed for each
of the five dependent variables. Age groups were divided by quartiles. BMI groups
were “18.5–24.9”, “25–29.9”, “30–34.9” (g3) and “35 or more”(g4). RESULTS: Diabetes
prevalence was 7.7%; (OR adjusted for g3:2.3; 95% CI: 2.0–2.7; OR_g4: 4.2; CI:3.4-5.3),
Hypertension prevalence was 23.6%; (OR_g3: 3.4; CI:3.0–3.8; OR_g4: 5.8; CI: 4.8–6.9),
HA prevalence was 2.8%; (OR_g3: 1.7; CI: 1.3–2.1; OR_g4: 1.6; CI: 1.1–2.5), CA preva-
lence was 8.2%; (OR_g3: 1.6; CI: 1.3–1.8; OR_g4: 2.3; CI: 1.8–2.9), CD prevalence was
7.9%; (OR_g3: 1.7; CI: 1.4–2.0; OR_g4: 2.7; CI: 2.2–3.4). All the stated OR reached
statistical significance (p0.05 for OR_g4 in HA and p0.001 for all the rest of them).
CONCLUSIONS: The results show how the risk of the examined comorbidities
largely increases in those patients with BMI35. Considering its potential econom-
ical impact on Public Health, it would be required to design and implement effec-
tive strategies aimed at the early detection of subjects at risk and the provision of
adequate treatment, as well as to establish suitable preventive programmes.
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OBJECTIVES: No direct comparisons have been made between infliximab and
ustekinumab in the treatment of moderate to severe psoriasis. A mixed treatment
comparative (MTC) meta-analysis was conducted to compare the relative efficacy
of infliximab and ustekinumab for the treatment of moderate to severe plague
psoriasis. METHODS: Randomized clinical trials that included infliximab, 5 mg/kg,
ustekinumab 45 mg or ustekinumab 90 mg in the treatment arm and reported PASI
75 and PASI 90 endpoints were identified from a systematic literature search. The
log odds ratio (log OR) was used as the treatment effect measure using both fixed-
effects and random-effects MTC models. Six trials meeting the inclusion criteria
were included in the mixed treatment networks to estimate relative efficacy.
RESULTS: The pooled odds ratio of achieving PASI 75 was 164.4 (95% (CI): 78.3 –
330.1) for infliximab, 77.9 (95% CI: 49.3 - 121.1) for ustekinumab 90 mg and 59.8 (95%
CI: 37.9 - 92.3) for ustekinumab 45 mg compared to placebo. Pairwise comparison
suggested that infliximab is significantly better than and ustekinumab 45 mg to
achieve PASI 75 (p 0.05). Pooled odds ratio of achieving PASI 90 was 172.6 (95% CI:
46.7 - 525.2) for infliximab, 79.6 (95% CI: 39.2 - 155.2) for ustekinumab 90 mg and 65.5
(95% CI: (32.1 - 127.8) for ustekinumab 45 mg. Similarly, there was a statistically
significant difference between infliximab and ustekinumab 45 mg in attaining PASI
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